Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones

OBJECTIVE: The use of thiazolidinediones (TZDs) as insulin sensitizers has been shown to have side effects including increased accumulation of bone marrow adipocytes (BMAds) associated with a higher fracture risk and bone loss. A novel TZD analog MSDC-0602K with low affinity to PPARγ has been develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Benova, Andrea, Ferencakova, Michaela, Bardova, Kristina, Funda, Jiri, Prochazka, Jan, Spoutil, Frantisek, Cajka, Tomas, Dzubanova, Martina, Balcaen, Tim, Kerckhofs, Greet, Willekens, Wouter, van Lenthe, G. Harry, Alquicer, Glenda, Pecinova, Alena, Mracek, Tomas, Horakova, Olga, Rossmeisl, Martin, Kopecky, Jan, Tencerova, Michaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508355/
https://www.ncbi.nlm.nih.gov/pubmed/36103974
http://dx.doi.org/10.1016/j.molmet.2022.101598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508355/
https://www.ncbi.nlm.nih.gov/pubmed/36103974
http://dx.doi.org/10.1016/j.molmet.2022.101598

Ejemplares similares